What a difference a year makes
Destiny has transformed its position, both in fundamental terms and in share price strength. A year ago, the group was navigating the conduct of its Phase 2b clinical trial through the challenges of the pandemic. 12 months on, positive results from that study, the acquisition of another Phase 3-ready program, plus a successful fundraising have all reshaped Destiny’s investment proposition.The costs and news flow of Destiny’s US Phase 2b study rightly dominated its FY 2020 financial results. Operating expenses increased to £6.4m (£5.7m in FY 2019), including R&D costs of £4.5m, and £1.9m in other administrative costs (£3.8m and £1.9m in FY 2019, respectively). With positive results announced recently, this higher expense should be seen as money well spent.
As well as the acquisition of NTCD-M3 for the prevention of Clostridioides difficile infection recurrence, (making two wholly-owned Phase 3-ready assets), the portfolio has grown in the last 12 months to include the pre-clinical, but very contemporary, SporCov COVID-19 collaboration, and XF-73 in dermal infections.
Financial forecasts have been updated for Destiny’s FY 2020 results, while our valuation has only adjusted slightly for the YE cash balance. Our fair value of Destiny Pharma has modestly increased to £214m, or 358p per share.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.